BUZZ-Hims & Hers rises after plan to sell Eli Lilly's weight loss drug on its platform

Reuters
04-02
BUZZ-Hims & Hers rises after plan to sell Eli Lilly's weight loss drug on its platform

** Shares of telehealth firm Hims & Hers HIMS.N rise 11.2% to $32.88

** HIMS says it plans to sell Eli Lilly's LLY.N weight-loss and diabetes drug on its platform

** Co says it will offer both branded versions of Lilly's tirzepatide, the active ingredient in weight loss drug Zepbound and diabetes medicine Mounjaro, as well as generics of Novo Nordisk's NOVOb.CO diabetes drug, liraglutide

** HIMS joins its peers such as Teladoc TDOC.N and LifeMD LFMD.O to offer Lilly's Zepbound ahead of restrictions on selling copies known as compounded drugs

** Including session's moves, HIMS stock up 36.4% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10